Xeris Biopharma (NASDAQ:XERS) Stock: Insider Steven Pieper Sells 5,000 Shares

Key Points

• Insider Steven Pieper sold 5,000 Xeris Biopharma shares at an average price of $9.41, generating $47,050. The Rule 10b5-1 transaction reduced his ownership by 0.37%, leaving him with 1.35 million shares.
• Xeris shares traded at $9.08, with the stock up from its 50-day and 200-day moving averages but still below its 52-week high of $11.33. The company recently missed quarterly earnings expectations, reporting a loss of $0.18 per share despite revenue exceeding estimates.
• Analyst sentiment is mixed: four analysts rate Xeris a Buy, two a Hold, and one a Sell, resulting in an overall Hold rating and an average price target of $12.80. Institutional investors own approximately 42.75% of the company.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $47,050.00. Following the sale, the insider owned 1,351,053 shares of the company's stock, valued at approximately $12,713,408.73. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, September 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $42,500.00.
• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $42,500.00.
• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.52, for a total value of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total value of $147,900.00.

Xeris Biopharma Price Performance

NASDAQ:XERS traded down $0.17 during mid-day trading on Friday, reaching $9.08. The stock had a trading volume of 1,375,716 shares, compared to its average volume of 1,988,684. The stock has a market capitalization of $1.66 billion, a P/E ratio of -82.55 and a beta of 0.53. The firm has a 50 day moving average price of $8.45 and a two-hundred day moving average price of $7.29. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $11.33.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). The business had revenue of $92.10 million for the quarter, compared to analysts' expectations of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. As a group, analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new position in shares of Xeris Biopharma during the second quarter valued at about $74,000. Allworth Financial LP lifted its holdings in Xeris Biopharma by 86.4% in the second quarter. Allworth Financial LP now owns 4,315 shares of the company's stock worth $34,000 after buying an additional 2,000 shares during the period. Allianz Asset Management GmbH purchased a new stake in Xeris Biopharma in the second quarter worth about $314,000. Corient Private Wealth LP bought a new stake in Xeris Biopharma during the 2nd quarter valued at approximately $1,458,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Xeris Biopharma during the 2nd quarter valued at approximately $89,000. Institutional investors own 42.75% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on XERS. Wall Street Zen upgraded shares of Xeris Biopharma from a "hold" rating to a "buy" rating in a report on Saturday, September 19th. Barclays raised their target price on Xeris Biopharma from $9.00 to $12.00 and gave the stock an "overweight" rating in a research note on Thursday, August 20th. Weiss Ratings lowered Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Finally, Leerink Partners lifted their price objective on Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a research report on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $12.80.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.